Selective inhibitors of AKT positively combine with PKC412 in the absence and presence of HS-5 SCM against MOLM13-luc+ cells.
- Ellen Weisberg (203474)
- Qingsong Liu (381059)
- Xin Zhang (35492)
- Erik Nelson (203494)
- Martin Sattler (203514)
- Feiyang Liu (381060)
- Maria Nicolais (381061)
- Jianming Zhang (139701)
- Constantine Mitsiades (381062)
- Robert W. Smith (381063)
- Richard Stone (86371)
- Ilene Galinsky (64265)
- Atsushi Nonami (381064)
- James D. Griffin (203544)
- Nathanael Gray (157494)
Publication date
February 2013
DOIAbstract
<p>(A–B) Approximately two-day proliferation studies performed with selective AKT inhibitors in combination with PKC412 in the presence of RPMI+10% FBS. (C–D) Approximately two-day proliferation studies performed with selective AKT inhibitors in combination with PKC412 in 80% HS-5 SCM. (E) Treatment of MOLM13-luc+ cells with PKC412 in either RPMI+10% FBS or 80% HS-5 SCM.</p
Add to ORKG